Cancers & treatments·Regimen libraryAdjuvant

CMF

Checked 2026-09-09

Historical adjuvant chemotherapy for early breast cancer; still an option when anthracyclines and taxanes are contraindicated

One cycle

every 28 days × 6 · about 24 weeks in total

28-day cycle × 6 (about 24 weeks)OralIntravenous Daily oral course

Components

Drug	Dose	Route	Days
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug)	100 mg/m² once daily	Oral	D1-14
Methotrexate Antifolate (DHFR inhibitor)	40 mg/m²	IV	D1, 8
Fluorouracil Fluoropyrimidine antimetabolite	600 mg/m²	IV	D1, 8

Cycles

28-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Notes

The first adjuvant chemotherapy shown to reduce breast cancer recurrence; anthracycline and taxane regimens later proved superior.

Used in

HR-positive / HER2-negative breast cancer HER2-positive breast cancer Triple-negative breast cancer (TNBC)

Products

CyclophosphamideMethotrexateFluorouracil (5-FU)

Source

Bonadonna, NEJM 1976: adjuvant CMF in node-positive breast cancer

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.